We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01025934
Recruitment Status : Completed
First Posted : December 4, 2009
Last Update Posted : December 4, 2009
Napoli CTO Hospital
Information provided by:
University of Campania "Luigi Vanvitelli"

Brief Summary:
The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.

Condition or disease Intervention/treatment Phase
Proliferative Diabetic Retinopathy Drug: Bevacizumab Other: sham Phase 4

Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 7 days Drug: Bevacizumab
Active Comparator: 20 days Drug: Bevacizumab
Sham Comparator: sham Other: sham

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • vitreous haemorrhage
  • tractional retinal detachment
  • active proliferative diabetic retinopathy.

Exclusion Criteria:

  • neovascular glaucoma
  • cataract
  • combined traction and rhegmatogenous RD

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT01025934     History of Changes
Other Study ID Numbers: IVBDRNA
First Posted: December 4, 2009    Key Record Dates
Last Update Posted: December 4, 2009
Last Verified: December 2009

Additional relevant MeSH terms:
Retinal Diseases
Diabetic Retinopathy
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents